Emory University's Rollins School of Public Health: Analysis Suggests Additional Evidence Necessary for Surrogate Markers Used as Endpoints Used to Support FDA Drug Approvals
April 23, 2024
April 23, 2024
ATLANTA, Georgia, April 23 (TNSres) -- Emory University's Rollins School of Public Health issued the following news release:
Clinical trials supporting the approval of drugs by the U.S. Food and Drug Administration (FDA) increasingly use surrogate markers, such as imaging findings or laboratory measures, as primary endpoints. Surrogate markers, which offer the advantage of reducing the duration and size of clinical trials, are expected to predict target clinical outcomes of interest . . .
Clinical trials supporting the approval of drugs by the U.S. Food and Drug Administration (FDA) increasingly use surrogate markers, such as imaging findings or laboratory measures, as primary endpoints. Surrogate markers, which offer the advantage of reducing the duration and size of clinical trials, are expected to predict target clinical outcomes of interest . . .